<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775578/" ref="ordinalpos=2345&amp;ncbi_uid=5309654&amp;link_uid=PMC3775578" image-link="/pmc/articles/PMC3775578/figure/F1/" class="imagepopup">Figure 1. The Hedgehog (Hh) <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>.  From: Novel investigational drugs for basal cell carcinoma. </a></div><br /><div class="p4l_captionBody"><b>A.</b> In the absence of Hh ligand, Ptch1 in the primary cilium represses Smo function, resulting in the proteolytic processing of Gli-activator (Gli1-A) (bound to SuFu, a negative regulator of Hh signaling) to Gli-repressor (Gli-R). The latter then binds to the promoters of Hh target genes to repress transcription. <b>B.</b> In the presence of Hh, Ptch1 translocates out of the cilium and is degraded, allowing Smo to enter the cilium and activate the Hh pathway by preventing cleavage of Gli proteins to its repressor form. Gli-A enters the nucleus and activates Hh-target gene (e.g., Gli1, Ptch1, Bcl2, FoxM1) transcription.</div></div>